SCHEMBL3018735

SCHEMBL3018735

COc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3cc(Cl)ccc3OC)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.46
KDM1A O60341 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.43
RAB9A P51151 5/20 0.43
NPC1 O15118 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
REV1 Q9UBZ9 1/20 0.41
CPT1A P50416 1/20 0.41
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
DRD2 P14416 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003767 0.94 AR (0.46) ARKDM1ASMN1; SMN2RAB9ANPC1
SCHEMBL3020564 0.93 ALPL (0.42) ARKDM1ASMN1; SMN2RAB9ANPC1
SCHEMBL3017808 0.92 AR (0.46) ARKDM1ASMN1; SMN2RAB9ANPC1
SCHEMBL15671685 0.90 REV1 (0.50) ARSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3016507 0.90 RAB9A (0.50) ARSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3016536 0.90 REV1 (0.49) ARSMN1; SMN2RAB9ANPC1ALDH1A1
SCHEMBL3022225 0.90 AR (0.53) ARSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3003825 0.90 SMN1; SMN2 (0.42) ARKDM1ASMN1; SMN2RAB9ANPC1
SCHEMBL3010772 0.89 AR (0.47) ARSMN1; SMN2RAB9ANPC1KDM4E
SCHEMBL3010963 0.89 AR (0.46) ARSMN1; SMN2RAB9ANPC1REV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885KDM1A 3548/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.